HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Zydus Lifesciences’ arm launches generic of phenylpropanolamine hydrochloride tablets
Sep-16-2025

Zydus Lifesciences’ step down wholly owned subsidiary – ZyVet Animal Health has released the first FDA-approved generic of phenylpropanolamine hydrochloride tablets, a trusted treatment for managing urinary incontinence in dogs. This latest product underscores ZyVet’s mission to bring trusted, high-quality, and cost-effective therapies to veterinary professionals across the United States.

Phenylpropanolamine hydrochloride is commonly prescribed to treat urinary incontinence in dogs due to urethral sphincter hypotonus. Often seen in spayed females and aging dogs, urethral sphincter hypotonus can lead to frustrating and embarrassing accidents. ZyVet’s generic provides dependable symptom relief while supporting stronger long-term client compliance. Available in multiple strengths to support precise dosing, the product is designed with the needs of both veterinary teams and pet owners in mind. 

ZyVet’s rapid portfolio expansion leads a paradigm shift in the industry reinforcing that generic animal health products are as effective as the pioneer brands. As a division of Zydus Lifesciences, ZyVet benefits from more than 70 years of pharmaceutical, R&D, Regulatory, QA/QC, manufacturing scale, excellence and expertise. ZyVet Animal Health, a leader in affordable generic pharmaceuticals for animals, is a wholly owned subsidiary of Zydus Pharmaceuticals (USA) Inc., itself a wholly owned subsidiary of Zydus Lifesciences.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

  RELATED NEWS >>